Pancreatic cancer trial aims to supercharge immune system before surgery
NCT ID NCT06048484
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding drugs that block the tumor's immune-evasion pathways to standard radiation and immunotherapy can boost the body's immune attack on pancreatic cancer before surgery. About 60 patients with advanced pancreatic cancer who are candidates for surgery will receive different combinations of these drugs along with radiation. The main goal is to see if these combos increase cancer-fighting immune cells in the tumor and improve surgical outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Zimberelimab, Quemliclustat, Etrumadenant, modified FOLFIRINOX, and stereotactic body radiotherapy
What this could lead to
If successful, this could improve immune attack on pancreatic tumors, potentially increasing surgical success and long-term control.
What could go wrong
This is an early phase 2 trial with only 60 participants. The added drugs may cause more side effects, and the immune response may not translate to better outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Email: •••••@•••••
-
Northwell Health R.J. Zuckerberg Cancer Center
RECRUITINGLake Success, New York, 11042, United States
Contact Email: •••••@•••••
Contact
-
UNC Hospitals, The University of North Carolina at Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27514, United States
Contact Phone: •••-•••-••••
-
University of Pennsylvania, Abramson Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••